1. Introduction
Given the ageing population, mental health of older adults is becoming a public health concern. It is estimated that one third of individuals older than 65 years have experienced a mental illness during the past year [Reference Andreas, Schulz, Volkert, Dehoust, Sehner and Suling1]. Depression is a leading cause of disability of older adults and is associated with cognitive and physical decline, poor quality of life and excess mortality [Reference Kohler, Evangelou, Stubbs, Solmi, Veronese and Belbasis2]. Previous studies indicate that the prevalence of late-life depression (LLD) largely varies across Europe [Reference Andreas, Schulz, Volkert, Dehoust, Sehner and Suling1, Reference Van de Velde, Bracke and Levecque3–Reference Castro-Costa, Dewey, Stewart, Banerjee, Huppert and Mendonca-Lima9]. Some studies suggested a higher burden of LLD in Southern and Central Eastern Europe (CEE), when compared to Western European and Scandinavian countries [Reference Van de Velde, Bracke and Levecque3–Reference Hansen and Slagsvold5, Reference Bøe, Balaj, Eikemo, McNamara and Solheim7, Reference Castro-Costa, Dewey, Stewart, Banerjee, Huppert and Mendonca-Lima9]. However, the reasons for this large variation are not clear and the region of CEE has been well represented only in a few studies [Reference Van de Velde, Bracke and Levecque3, Reference Hansen and Slagsvold5, Reference Bøe, Balaj, Eikemo, McNamara and Solheim7].
LLD is a multifactorial disorder influenced by genes, environment and gene-environmental interactions, suggesting that it is to some extent preventable [Reference Kohler, Evangelou, Stubbs, Solmi, Veronese and Belbasis2]. Risk factors are substantially different for LLD when compared to depression in younger individuals [Reference Kessler, Birnbaum, Bromet, Hwang, Sampson and Shahly10–Reference Gertner, Domino and Dow12]. For example, socioeconomic conditions have been suggested as predictors of depression especially in younger cohorts, while in older participants, depression may mostly be influenced by frequency of social meetings, marital status and contact with children and grandchildren [Reference Bøe, Balaj, Eikemo, McNamara and Solheim7, Reference Tsai, Motamed and Rougemont13]. In addition, LLD is in a strong, reciprocal relationship with many chronic diseases, such as cancer, cardiovascular diseases (CVD) or cognitive impairment, which in turn may lead to pain, disability as well as higher risk of death [Reference Enache, Fereshtehnejad, Kareholt, Cermakova, Garcia-Ptacek and Johnell14–Reference Molero, Ángel, Ruiz‐Canela and Lahortiga16]. Unhealthy behaviours such as smoking, alcohol abuse and physical inactivity may be important mediators in these associations [Reference Miloyan and Fried17].
There is robust evidence demonstrating that although depression in older adults may be more difficult to treat than in younger individuals, comprehensive treatment schemes combining psychosocial, medical and pharmacological approaches are helpful [Reference Unützer, Katon and Callahan18]. However, there is a substantial gap between older adults experiencing symptoms of LLD and those who are detected by mental health services (MHS) and are then treated [Reference Reynolds and Patel19]. Increasing detection of LLD in primary care, which is the most frequent point of contact between older adults and health care system, is a crucial strategy to reduce the burden of depression, improve the quality of life and prevent suicides in old age [Reference Gregg, Fiske and Gatz20].
Reasons for under-detection of LLD are multi-faceted, and include patients, physicians as well as societal factors [Reference Goldberg21–Reference Angermeyer, van der Auwera, Carta and Schomerus23]. First, older adults are less likely than younger adults to recognize signs of depression and to perceive a need for using MHS to seek treatment [Reference Mackenzie, Pagura and Sareen22]. Second, symptoms of LLD differ from those observed in younger populations and diagnosis of LLD by physicians is complicated by co-existent cognitive and somatic diseases [Reference Goldberg21]. Specifically, fatigue, cognitive impairment, apathy and other signs of LLD may be falsely perceived as a result of chronic somatic illness and not as a separate mental illness. Third, societal stigma towards mental disorders may prevent acknowledgment of the illness and be a barrier to MHS use [Reference Angermeyer, van der Auwera, Carta and Schomerus23].
European countries differ widely in the public burden of unhealthy behaviours, opportunities for older adults, health care policies concerning the treatment of depression as well as attitudes towards mental illness [Reference Van de Velde, Bracke and Levecque3–Reference Van de Velde, Bracke and Levecque9]. Previous studies on the burden of LLD across Europe have been conducted either as social surveys, studies focusing on somatic comorbidities or differences on the macro-level in mental health care system, but, to the best of our knowledge, no study has taken all relevant factors into account. Our objective was to (1) determine the prevalence of LLD in 4 European regions: Western Europe, Scandinavia, Southern Europe and CEE; (2) determine which socio-demographic, social and health-related factors are associated with LLD and (3) explore the gap in MHS use for LLD and factors that relate to it.
2. Methods
2.1. Source of data
We performed a cross-sectional study based on data from the Survey on Health, Ageing and Retirement in Europe (SHARE). SHARE is a multidisciplinary and cross-national study that aims to understand the trajectories of health, social network and economic conditions of the aging population in 27 European countries and Israel [Reference Börsch-Supan, Brandt, Hunkler, Kneip, Korbmacher and Malter24]. The target population were individuals aged 50 years and more, speaking the official language of the country and not living abroad or in an institution during the duration of the field work. If they had a partner, their partners were also eligible to be included irrespective of age. The collection of data was performed by computer-assisted personal interviewing (CAPI). The first wave of interviews was conducted in 2004 and was followed by 5 subsequent waves in approximately 2-year intervals, with the 6th wave being completed in 2015.
The sampling was based on probability selection, but the sampling frames were allowed to vary between countries. For example, stratified simple random sampling from national population registers was chosen in Denmark and Sweden, while multi-stage sampling using regional or local population registers was performed in Germany, Italy and Spain. Single or multi-stage sampling using telephone directories followed by screening in the field was used in Austria, Greece and Switzerland. New individuals were enrolled as refreshment samples in order to compensate for the drop out of participants. Methodological details about the study are available on http://www.share-project.org/.
2.2. Standard protocols, approvals and participants´ consent
This paper uses data from the 6th wave of SHARE, see elsewhere for details [Reference Börsch-Supan, Brandt, Hunkler, Kneip, Korbmacher and Malter24] (DOI: 10.6103/SHARE.w6.600). SHARE has been repeatedly reviewed and approved by the Ethics Committee of the University of Mannheim. All participants provided written consent. Their data were pseudo-anonymized and they have been informed about the storage and use of the data and their right to withdraw consent. The present analysis was approved by the Ethics Committee of the National Institute of Mental Health, Czech Republic.
2.3. Assessment of depression
Depression was assessed using EURO-D scale, which was administered by centrally trained interviewers as a part of CAPI. The EURO-D scale was originally developed to compare symptoms of LLD across 11 European countries in the EURODEP Concerted Action Programme [Reference Prince, Reischies, Beekman, Fuhrer, Jonker and Kivela25] and has been used in many epidemiological studies. The 12 EURO-D items (depressed mood, pessimism, wishing death, guilt, sleep, interest, irritability, appetite, fatigue, concentration, enjoyment and tearfulness) are scored 0 (symptom not present) or 1 (symptom present), generating an ordinal scale with a maximum score of 12. Higher scores are suggestive of a greater severity of depressive symptoms.
Even though it could be more accurate to assess degrees of appearance of depressive symptoms over time, as used in previous studies [Reference Andreas, Schulz, Volkert, Dehoust, Sehner and Suling1, Reference Winkler, Formanek, Mlada and Cermakova26], rather than the presence of symptoms, we utilize this ordinal scale in the present study in order to capture current symptomatology. EURO-D scale is not a diagnostic instrument, however, previous studies suggest that reaching 4 or more points on this scale indicate the presence of major depression [Reference Prince, Reischies, Beekman, Fuhrer, Jonker and Kivela25]. Here, we created a binary variable where 4 or more points stood for LLD (coded as 1, relative to 0=no depression).
2.4. Gap in use of MHS
The gap in MHS use has been widely defined as a proportion of persons that do not utilize MHS out of persons that have a diagnosable mental disorder [Reference Kohn, Saxena, Levav and Saraceno27]. In this present study, we operationalize utilization of MHS by combining two pieces of information: self-reported diagnosis (when the participants positively answered a question whether they have been told by a doctor that they have affective or emotional disorders) and self-reported medication (when the participants answered positively to a question whether they are using drugs against depression or anxiety). Individuals that answer positively to either item are classified as having utilized MHS. Thus, the gap in MHS use is represented by individuals that have prevalent depression but have received neither a diagnosis nor treatment.
2.5. Covariates
We identified covariates based on literature as sociodemographic and social characteristics, comorbidities and general health-related factors that may be associated with LLD and the MHS use. Sociodemographic characteristics were age, gender, years of education, type of residence, immigration, current job situation and household income. Social characteristics included family status, number of children, number of grandchildren and number of persons with whom the person has daily contact. Comorbidities included CVD, cancer, cognitive impairment, number of chronic diseases and whether the participant is troubled by pain. General health-related factors contained information about physical activity, body mass index (BMI), alcohol use, smoking, instrumental activities of daily living (IADL), grip strength and computer use. Detailed definition of covariates is provided in the Supplement.
2.6. Study sample
We focused on older adults, defined as persons aged 65 years or older, as previously used [Reference Cermakova, Formanek, Kagstrom and Winkler28], and studied individuals who participated in the 6th wave of SHARE in 2015. We excluded participants from Israel (n = 1 357) in order to focus only on European regions. Further, we excluded individuals who had missing data on depressive scores (n = 2 408), leaving the sample of 36 069 (55% women; mean age 74 years old), from which the prevalence of LLD is derived. Individuals excluded due to missing data on depressive scores were older (median 80 vs. 73; p < 0.001) and less educated (mean 8 vs. 10 years of education; p < 0.001) compared to the final analytical sample.
For statistical analysis, we additionally excluded individuals that had missing data on covariates (n = 7 273), leaving 28 796 participants in the final analytical sample (53% women; mean age 74 years old). The individuals excluded due to missing data on covariates had a higher frequency of LLD than those included in the analysis (39% vs. 27%; p < 0.001). Four European regions were represented in the final analytical sample: Western Europe (Austria, Germany, Switzerland, Belgium, France, Luxembourg; n = 9 940), Southern Europe (Spain, Italy, Portugal, Greece; n = 7 022), CEE (Czech Republic, Poland, Hungary, Slovenia, Estonia, Croatia; n = 7 845) and Scandinavia (Sweden, Denmark; n = 3 989). A flowchart is presented in Supplemental Figure S1.
2.7. Statistical analysis
We present the prevalence of LLD and the gap in MHS use in the whole sample as well as stratified by region. First, we report the crude number and second, we use calibrated cross-sectional sampling weights based on the procedure by Deville and Särndal [Reference Deville and Särndal29]. Weighting enables us to reduce the potential selection bias generated by participants´ non-response at baseline and refreshment samples of each wave and sample attrition. The weights were calculated for 8 age-groups, gender and region according to the regional demographic statistics given by Eurostat.
To compare persons with and without LLD, we used an independent sample t-test for continuous variables with normal distribution, Mann-Whitney test for continuous variables with skewed distribution and χ 2test for binary variables. We considered covariates that were statistically significant in univariate analysis at the level of p < 0.001 (given the large sample size and multiple predictors tested) to be included in multivariable analysis. We then applied binary logistic regression to estimate odds ratio (OR) with 95% confidence interval (CI) for the association of individual covariates with LLD. The final model included covariates that were significantly associated with the dependent variable or improved the pseudo R2 of the model.
We performed dominance analysis to calculate the relative importance of each covariate in the final models and proportion of variance explained by them [Reference Azen and Traxel30]. The output from the dominance analysis are standardized weights, which are the general dominance weights from McFadden R2 normed to be out of 100%. Based on these, we selected the 5 most important covariates that explain the highest proportion of the variance of LLD. In the end, we studied individuals classified with LLD and explored factors associated with the MHS use. We performed univariate and multivariable analysis as described above. Analyses were performed using STATA (Version 15.1).
3. Results
From the 36 069 individuals in the sample, 10 483 (29%) were classified with LLD. The prevalence was highest in Southern Europe (35%), followed by CEE (32%), Western Europe (26%) and the lowest in Scandinavia (17%; p < 0.001 from ANOVA; Fig. 1A). Using sampling weights, the prevalence in the whole sample was 33% and was highest in CEE (42%), followed by Southern Europe (37%), Western Europe (29%) and Scandinavia (18%).
Individuals classified with LLD were older, had a lower socioeconomic status and had more comorbidities (Table 1). In multivariable analysis, the model that best explained the variation in LLD included gender, age, household net income, family status, CVD, cancer, cognitive impairment, total number of chronic diseases, BMI, physical inactivity, IADL, pain, grip strength and computer use (Supplemental Table S1). We observed several differences in analyses stratified by gender and region (Supplemental Tables S1 and S2).
According to dominance analysis (Table 2), the most important factors in the final model were total number of chronic diseases, pain, IADL, grip strength and cognitive impairment, which together explained 73% of the variance of LLD. When stratified by gender, the same 5 variables were observed to be the most important for women, while for men, physical activity took the 4th rank in the dominance analysis, replacing grip strength. Stratification by region revealed that number of chronic diseases, pain, IADL and grip strength are thefour most important factors in all regions. The 5th rank was taken by gender in Western Europe, cognitive impairment in Southern Europe and CEE and physical inactivity in Scandinavia.
The gap in MHS use was 79% in the whole sample and was lower in Western and Southern Europe (both 76%) and higher in Scandinavia and CEE (both 83%; Fig. 1B). Using sampling weights, the gap in MHS use in the whole sample was also 79%. Service users were younger, more frequently women and had more comorbidities (Table 3). In multivariable analysis, use of MHS was associated with a higher number of chronic diseases, more limitations in IADL, lower age, female gender, cognitive impairment and lower BMI (Table 4). The single most important factor was number of chronic diseases, which explained 67% of variance of the model. It was the most dominant factor in all regions and for both genders (not presented in tables).
IQR, interquartile range; SD, standard deviation; IADL, instrumental activities of daily living limitations.
IADL, instrumental activities of daily living; OR, odds ratio; CI, confidence interval.
The models included gender, age, household net income, family status, CVD, cancer, cognitive impairment, total number of chronic diseases, BMI, physical inactivity, IADL, pain, grip strength and computer use.
4. Discussion
In this population-based cohort study of approximately 30 000 individuals, uniquely large and well-characterized nationally representative older adults from 17 European countries, we found that approximately 30% of Europeans older than 65 years may have LLD, as suggested by higher scores on a common depression symptoms scale. The rate of LLD was highest in Southern Europe and CEE and lowest in Scandinavia. Depression was associated strongest with somatic comorbidities and physical and cognitive functioning. We observed a large gap in MHS use for LLD that reached almost 80%.
Similar regional differences, pointing towards the highest burden of LLD in CEE and Southern Europe, were observed in the European Social Study [Reference Van de Velde, Bracke and Levecque3], COMPARE study [Reference Kok, Avendano, d’Uva and Mackenbach4] and Generations and Gender Survey [Reference Hansen and Slagsvold5]. However, the European MentDis_ICF65+ study suggested a lower prevalence of major depressive episode in older adults residing in Southern Europe, when compared to their counterparts from Western Europe [Reference Andreas, Schulz, Volkert, Dehoust, Sehner and Suling1]. On the contrary, our findings are in accord with global literature reporting higher rates of depression in countries with poorer living conditions, lower welfare provision and higher income inequality [Reference Patel, Burns, Dhingra, Tarver, Kohrt and Lund31, Reference Kessler and Bromet32]. It can be speculated that richer and stronger welfare states may reduce the burden of LLD by supporting older people to be independent and providing social and public services.
Although we observed some small gender and regional differences in the associations of LLD to various factors, the dominance analysis demonstrated that the most important factors that explain the variation in the prevalence of depression are similar for men and women as well as individuals residing in different European regions. As opposed to previous studies that emphasized the effect of social and family factors as well as unhealthy behaviours in the development of LLD [Reference Seeman33, Reference Devanand34], we show that the most important factors that explained the highest proportion of variation in LLD were related to somatic health and physical and cognitive functioning. This is in line with a large prospective cohort study showing that physical and functional limitation is the largest contributor to the risk of LLD [Reference Chang, Pan, Kawachi and Okereke35] and a recent meta-analysis suggesting a high correlation between physical multi-morbidity and depression [Reference Stubbs, Vancampfort, Veronese, Kahl, Mitchell and Lin36].
The 79% gap in MHS use observed in this study suggests that the disparity in the service utilization for LLD is much higher than that reported for the global population (ages 15+) with depression, which is estimated to be 56% [Reference Kohn, Saxena, Levav and Saraceno27]. The number of somatic disorders was positively associated with utilization of MHS, indicating that persons with comorbid diseases have frequent contact with health services, where depression may get diagnosed and treated. On the contrary, LLD may go unnoticed in adults who do not visit physicians due to somatic disorders. We propose several changes for decreasing the burden of LLD and closing the gap in MHS use. First, this gap could be addressed by promoting help-seeking behaviour in older adults. Since perception of need for help is impaired by a lack of knowledge, prejudice, self-stigmatization and discrimination, even by medical staff [Reference Schomerus, Stolzenburg, Freitag, Speerforck, Janowitz and Evans-Lacko37, Reference Stolzenburg, Freitag, Evans-Lacko, Speerforck, Schmidt and Schomerus38], we propose that physicians adopt highly professional behavior including non-stigmatizing approaches to care. With ageism being highly prevalent, socially accepted, usually unchallenged [Reference Cuddy, Norton and Fiske39], and standing as a barrier in seeking help through MHS [Reference Robb, Chen and Haley40], stigma reduction initiatives should be implemented in all levels of medical education given the current demographic transition. In addition, portraying professional mental health treatment as extending beyond biomedical problems could contribute to closing the gap in MHS utilization [Reference Stolzenburg, Freitag, Evans-Lacko, Speerforck, Schmidt and Schomerus38].
Because primary care is the preferred care setting for older adults [Reference Hall and Reynolds-Iii41], understanding of LLD by general practitioners needs to be improved and its detection should be increased, using evidence-based guidelines [Reference Smith, Haedtke and Shibley42]. We suggest that general practitioners look for symptoms of depression in particular in individuals that have several chronic somatic conditions and are limited in functioning, with instruments specific for their age. There are several screening tools validated in a geriatric and primary care setting: the Geriatric Depression Scale [Reference Mitchell, Bird, Rizzo and Meader43], Center for Epidemiologic Studies Depression Scale [Reference Beekman, Deeg, Van Limbeek, Braam, De Vries and Van Tilburg44], Patient Health Questionnaire 2 and 9 [Reference Manea, Gilbody, Hewitt, North, Plummer and Richardson45–Reference Kroenke, Spitzer and Williams47] and The Hospital Anxiety and Depression Scale [Reference Zigmond and Snaith48].
Prevention is needed in individuals who are at risk of depression or are already mildly symptomatic [Reference Hall and Reynolds-Iii41]. The literature reports effective interventions for prevention of LLD that are feasible in primary-care setting [Reference van’t Veer-Tazelaar, van Marwijk and van Oppen49]. For example, a pragmatic randomized trial identified that a stepped-care program targeting older adults with mild depressive symptomatology reduced the incidence of depression, when compared to usual care. This intervention consisted of tiers of watchful waiting, cognitive behaviour therapy-based bibliotherapy, cognitive behaviour therapy-based problem solving and pharmacological medication, if required [Reference van’t Veer-Tazelaar, van Marwijk and van Oppen49]. Further, there are effective primary care-based interventions for the treatment of LLD [Reference Unutzer, Katon, Callahan, Williams, Hunkeler and Harpole50]. For example, a randomized controlled trial concluded that a collaborative care management program providing access to a depression care manager who offered education, personally tailored pharmacotherapy, psychotherapy and a course in problem solving was significantly more effective at depression treatment compared with usual care [Reference Unutzer, Katon, Callahan, Williams, Hunkeler and Harpole50].
IQR, interquartile range; SD, standard deviation; IADL, instrumental activities of daily living.
OR, odds ratio; CI, confidence interval; BMI, body mass index; IADL, instrumental activities of daily living.
*p < 0.05; **p < 0.001.
This study is strengthened by a population-based design and a large sample size, including individuals from CEE that have been underrepresented in previous studies [Reference Winkler, Formanek, Mlada and Cermakova26] and can be generalized to adults aged 65 years or older residing in Europe. Several limitations should be noted: There are potential residual confounders, such as genetics or past sociodemographic and health related factors. Furthermore, the indicator of MHS utilization was constructed based on self-reported information, which may not be accurate due to several reasons, such as cognitive impairment or participants´ lack of awareness of taking antidepressants. This can bias our findings and overestimate the gap of MHS utilization found in the present study. In addition, reporting of some factors, such as pain or IADL may have been influenced by depressed mood, thus differentially misclassified, potentially overestimating their association with depression.
Availability of data and materials
Access to the SHARE data is provided free of charge on the basis of a release policy that gives quick and convenient access to all scientific users world-wide after individual registration. All details about the application and registration process can be found on this website: http://www.share-project.org. The study protocol and syntax of the statistical analysis will be shared upon request from the corresponding author of this study.
Acknowledgements
This paper uses data from SHARE Wave 6 (DOIs: 10.6103/SHARE.w6.600), see Börsch-Supan et al. (2013) for methodological details1. The SHARE data collection has been primarily funded by the European Commission through FP5 (QLK6-CT-2001-00360), FP6 (SHARE-I3: RII-CT-2006-062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-028812) and FP7 (SHARE-PREP: N°211909, SHARE-LEAP: N°227822, SHARE M4: N°261982). Additional funding from the German Ministry of Education and Research, the Max Planck Society for the Advancement of Science, the U.S. National Institute on Aging (U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_AG025169, Y1-AG-4553-01, IAG_BSR06-11, OGHA_04-064, HHSN271201300071C) and from various national funding sources is gratefully acknowledged (see www.share-project.org). The authors were supported by the Sustainability for the National Institute of Mental Health” (grant LO1611), with a financial support from the Ministry of Education, Youth and Sports of the Czech Republic.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.eurpsy.2018.12.002.
Comments
No Comments have been published for this article.